Ataluren (TranslarnaTM) enables read-through of premature stop codons in mRNA to produce full-length and functional dystrophin protein and had been conditionally approved by the European Medicines Agency (EMA) for the treatment of DMD patients with nonsense mutation. Here, DMD is linked to Duchenne muscular dystrophy.